Brief description of measure CMS646: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer: Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging. Description of issue The denominator exception language in the header does not clearly describe the logic and timing. The measure developer would like to reduce confusion by implementers and provide additional language. Goal of review Obtain clinical feedback

Proposed solution CURRENT Denominator Exception: Unavailability of BCG PROPOSED Denominator Exception: Unavailability of BCG within 6 months after Bladder Cancer Staging Rationale for change ​This change will align the denominator exception language with the existing logic and timing.